The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc has applied for supplementary protection certificates for Strangvac in key European markets
Stockholm, February 1, 2022 – The European patent for Strangvac®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the...New study confirms that Strangvac is likely to be effective against all known strains of Streptococcus equi
Stockholm, January 21, 2022 – In the largest study of its kind, published in the ‘Equine Veterinary Journal’, scientists confirm that the antigens used in the Strangvac vaccine were highly conserved regardless of which strain of Streptococcus equi...Clarification regarding Intervacc’s vaccine Strangvac
Stockholm, December 17, 2021 – Due to the large and volatile trading in the company’s share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales throughout the EU and that sales will start...Intervacc comments on the trading halt of the company’s share on Nasdaq First North
Stockholm, December 15, 2021 – Nasdaq Stockholm has decided to temporarily stop trading in Intervacc after a volatile trading session and a decline in the share price. The reason for the price decline is speculation in social media about the company’s...Sales launch of Intervacc vaccine against equine Strangles during Q1 2022
Stockholm, December 14, 2021 – Intervacc AB (“Intervacc”) announces today that sales of the company’s Strangles vaccine Strangvac are planned to begin in the first quarter of 2022. Intervacc’s vaccine against equine Strangles, a widespread and common...Nyhetstjänster
